Progen Pharmaceuticals (www.progen. will use Quintiles’ ( services for clinical development-related projects. This agreement includes the execution of the Phase III trial of anticancer drug PI-88 for the treatment of primary liver cancer (hepatocellular carcinoma). Progen says that it is on track to initiate recruitment in the fourth quarter of 2007.

Previous articleScientists Find Diabetes Drug Kills p53-deficient Cancer Cells
Next articleApplied Biosystems Launches Genotyping Service Provider Program